The FDA on December 3,2021, approved KEYTRUDA® for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with Stage IIB or IIC melanoma following complete resection. KEYTRUDA® is a product of Merck.
Bottom Ad
Advertisement
Subscribe
